Stand Up To Cancer (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to ...

Proteins are essential components of cellular life, uniquely translating genetic information into a vast array of molecular ...

The first drugs against Alzheimer's disease that are intended to slow down the progression of the condition will soon be authorized in Germany. On November 14, 2024, the EMA granted approval for ...

(12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid ...

In a recent study, Tel Aviv Sourasky Medical Center has shed light on physician attitudes toward novel anti-amyloid ...

Earlier this year, the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued positive opinions for AT-02 for ATTR and light chain (AL) amyloidosis which were adopted by ...

Alnylam Pharmaceuticals has revealed new interim data from its Phase I trial of nucresiran, a ribonucleic acid interference ...